Research
May 07, 2026GLP-1 Primer for Dermatologists from the NPF Medical Board
Hear from the NPF Medical Board chair, Andrew Blauvelt, M.D., MBA, about the recently published Review article, “The National Psoriasis Foundation Primer on GLP-1 Receptor Agonists in Psoriasis: A Review” in JAMA Dermatology.
As the overlap between excess body weight and psoriatic disease is better understood, dermatologists are increasingly encountering patients on GLP-1 receptor agonists. The NPF Medical Board’s latest publication in JAMA Dermatology provides information on monitoring these patients within dermatology practice.
Key Considerations
- Documentation of therapy and baseline metrics
- Ongoing monitoring intervals and touchpoints
- Patient counseling on efficacy and adverse effects
- Screening for contraindications
As GLP-1 RAs become more common in patients with psoriatic disease, having a structured approach can support safer, more consistent care, even when dermatology is not the prescribing specialty.